IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA: UPDATED EFFICACY AND SAFETY OF THE RESONATE STUDY WITH UP TO FOUR YEARS OF FOLLOW-UP

被引：0

作者：

Moreno, C. ^{[1
]}

Byrd, J. C. ^{[2
]}

Hillmen, P. ^{[3
]}

O'Brien, S. ^{[4
]}

Barrientos, J. C. ^{[5
]}

Reddy, N. M. ^{[6
]}

Coutre, S. ^{[7
]}

Tam, C. S. ^{[8
,9
]}

Mulligan, S. P. ^{[10
]}

Jaeger, U. ^{[11
]}

Barr, P. M. ^{[12
]}

Furman, R. R. ^{[13
]}

Kipps, T. J. ^{[14
]}

Thornton, P. ^{[15
]}

Montillo, M. ^{[16
]}

Pagel, J. M. ^{[17
]}

Burger, J. A. ^{[18
]}

Jones, J. ^{[2
]}

Dai, S. ^{[19
]}

Vezan, R. ^{[19
]}

James, D. F. ^{[19
]}

Brown, J. R. ^{[20
]}

机构：

[1] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[2] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[3] Leeds Teaching Hosp, St James Inst Oncol, Leeds, W Yorkshire, England

[4] Univ Calif Irvine, Irvine, CA USA

[5] Hofstra Northwell Sch Med, Hempstead, NY USA

[6] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[7] Stanford Univ, Sch Med, Stanford, CA USA

[8] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[9] St Vincents Hosp, Melbourne, Vic, Australia

[10] Royal North Shore Hosp, Sydney, NSW, Australia

[11] Med Univ Vienna, Div Hematol & Hemostaseol, Vienna, Austria

[12] Univ Rochester, Med Ctr, Rochester, NY 14627 USA

[13] Weill Cornell Med Coll, New York, NY USA

[14] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

[15] Beaumont Hosp, Dublin, Ireland

[16] Osped Niguarda Ca Granda, Niguarda Canc Ctr, Milan, Italy

[17] Swedish Canc Inst, Hematol Malignancies Program, Seattle, WA USA

[18] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[19] Pharmacyclics LLC, Sunnyvale, CA USA

[20] Dana Farber Canc Inst, CLL Ctr, Boston, MA 02115 USA

来源：

HAEMATOLOGICA | 2017年 / 102卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

S769

引用

页码：311 / 311

页数：1

共 50 条

[1] Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study.
Byrd, John C.
Hillmen, Peter
O'Brien, Susan Mary
Barrientos, Jacqueline Claudia
Reddy, Nishitha M.
Coutre, Steven
Tam, Constantine S.
Mulligan, Stephen P.
Jager, Ulrich
Barr, Paul M.
Furman, Richard R.
Kipps, Thomas J.
Thornton, Patrick
Pagel, John M.
Burger, Jan Andreas
Jones, Jeffrey Alan
Dai, Sandra
Vezan, Remus N.
James, Danelle Frances
Brown, Jennifer R.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[2] Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
Munir, Talha
Brown, Jennifer R.
O'Brien, Susan
Barrientos, Jacqueline C.
Barr, Paul M.
Reddy, Nishitha M.
Coutre, Steven
Tam, Constantine S.
Mulligan, Stephen P.
Jaeger, Ulrich
Kipps, Thomas J.
Moreno, Carol
Montillo, Marco
Burger, Jan A.
Byrd, John C.
Hillmen, Peter
Dai, Sandra
Szoke, Anita
Dean, James P.
Woyach, Jennifer A.
AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (12) : 1353 - 1363
[3] Final Analysis From RESONATE: Six-Year Follow-Up in Patients With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma on Ibrutinib
O'Brien, Susan M.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (07) : 11 - 13
[4] Up to Seven Years of Follow-Up in the RESONATE-2 Study of First-Line Ibrutinib Treatment for Patients With Chronic Lymphocytic Leukemia
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (07) : 8 - 9
[5] Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
Barr, Paul M.
Owen, Carolyn
Robak, Tadeusz
Tedeschi, Alessandra
Bairey, Osnat
Burger, Jan Andreas
Hillmen, Peter
Coutre, Steve E.
Devereux, Stephen
Grosicki, Sebastian
McCarthy, Helen
Li, Jianyong
Simpson, David
Offner, Fritz C.
Moreno, Carol
Dai, Sandra
Szoke, Anita
Dean, James P.
Kipps, Thomas J.
Ghia, Paolo
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[6] Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study
Montillo, M.
O'Brien, S.
Tedeschi, A.
Byrd, J. C.
Dearden, C.
Gill, D.
Brown, J. R.
Barrientos, J. C.
Mulligan, S. P.
Furman, R. R.
Cymbalista, F.
Plascencia, C.
Chang, S.
Hsu, E.
James, D. F.
Hillmen, P.
BLOOD CANCER JOURNAL, 2017, 7 : e524 - e524
[7] Final Analysis of the RESONATE-2 Study: up to 10 Years of Follow-Up of First-Line Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Burger, Jan
Barr, Paul
Robak, Tadeusz
Owen, Carolyn
Tedeschi, Alessandra
Sarma, Anita
Patten, Piers E. M.
Grosicki, Sebastian
McCarthy, Helen
Offner, Fritz
Szafer-Glusman, Edith
Zhou, Cathy
Szoke, Anita
Neumayr, Lynne
Dean, James P.
Ghia, Paolo
Kipps, Thomas J.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S342 - S343
[8] Long-Term Follow-up, Up to 7 Years, in the RESONATE-2 Study of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL)
Burger, Jan
Barr, Paul
Owen, Carolyn
Robak, Tadeusz
Tedeschi, Alessandra
Bairey, Osnat
Hillmen, Peter
Coutre, Steve
Devereux, Stephen
Grosicki, Sebastian
McCarthy, Helen
Li, Jianyong
Offner, Fritz
Moreno, Carol
Dai, Sandra
Szoke, Anita
Dean, James P.
Kipps, Thomas J.
Ghia, Paolo
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S316 - S316
[9] Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib.
Barr, Paul M.
Munir, Talha
Brown, Jennifer R.
O'Brien, Susan Mary
Barrientos, Jacqueline Claudia
Reddy, Nishitha M.
Coutre, Steven
Tam, Constantine Si Lun
Mulligan, Stephen P.
Jager, Ulrich
Kipps, Thomas J.
Moreno, Carol
Montillo, Marco
Burger, Jan Andreas
Byrd, John C.
Hillmen, Peter
Dai, Sandra
Szoke, Anita
Dean, James P.
Woyach, Jennifer Ann
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[10] Ibrutinib for First-Line Treatment of Chronic Lymphocytic Leukemia in Patients Aged ≥65 Years: Results With 5 Years of Follow-Up for the RESONATE-2 Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 14 - 16

← 1 2 3 4 5 →